证券代码：300170 证券简称：汉得信息 公告编号：2025-048 上海汉得信息技术股份有限公司 关于实际控制人权益变动的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次权益变动系由公司实际控制人陈迪清因增持股份导致持股比例合计 由 4.73%增加至 5.00%，持股比例触及 5%。 2、本次权益变动为股东陈迪清增持，未触及要约收购，亦不会导致公司控 股股东、实际控制人发生变化，不会影响公司的治理结构和持续经营。 上海汉得信息技术股份有限公司（以下简称"公司"）于近日收到公司实际 控制人陈迪清出具的《详式权益变动报告书》。截至本公告披露日，信息披露义 务人因股份增持导致其持有公司股份占当前总股本的比例触及 5%。 根据《上市公司收购管理办法》和《证券期货法律适用意见第 19 号——《上 市公司收购管理办法》第十三条、第十四条的适用意见》规定"通过证券交易所 的证券交易，投资者及其一致行动人拥有权益的股份达到一个上市公司已发行股 份的 5%时，应当在该事实发生之日起 3 日内编制权益变动报告书，向中国证监 会、证券交易所提 ...

上海汉得信息技术股份有限公司 详式权益变动报告书 上市公司名称：上海汉得信息技术股份有限公司 股票上市地点：深圳证券交易所 1、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号— 权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上 市公司收购报告书》及其他相关的法律、法规、部门规章及规范性文件的有关规 定编写。 2、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本报 告书已全面披露信息披露义务人在上海汉得信息技术股份有限公司拥有权益的 股份。 股票简称：汉得信息 股票代码：300170 信息披露义务人：陈迪清 住所及通讯地址：中国上海市徐汇区**路***弄**号 签署日期：2025 年 9 月 15 日 权益变动性质：股份增加（通过证券交易所的集中交易）。 上海汉得信息技术股份有限公司 详式权益变动报告书 信息披露义务人声明 截至本报告书签署日，除本报告书披露的权益变动信息外，信息披露义务人 没有通过任何其他方式增加或减少其在上海汉得信息技术股份有限公司中拥有 权益的股份。 3、 ...

Group 1 - On September 15, Han's Information executed a block trade of 2.7665 million shares, with a transaction value of 48.8843 million yuan, accounting for 5.29% of the total transaction volume for that day [1][2] - The transaction price was 17.67 yuan, which was in line with the market closing price of 17.67 yuan [1][2]

9月11日，汉得信息涨5.89%，截至发稿，报18.34元/股，成交5.66亿元，换手率3.17%，总市值185.49亿 元。 资料显示，上海汉得信息技术股份有限公司位于上海市青浦区汇联路33号，成立日期2002年7月15日， 上市日期2011年2月1日，公司主营业务涉及ERP软件实施、客户支持和软件外包业务。主营业务收入构 成为：泛ERP32.98%，产业数字化-C2M31.65%，财务数字化-GMC23.18%，IT外包-ITO11.75%，其他 业务0.44%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 国寿安保创精选88ETF（159804）成立日期2020年3月4日，最新规模1.3亿。今年以来收益21.69%，同 类排名2024/4222；近一年收益66.12%，同类排名1203/3798；成立以来收益37.88%。 国寿安保创精选88ETF（159804）基金经理为李康、苏天醒。 截至发稿，李康累计任职时间10年179天，现任基金资产 ...

Group 1 - The core point of the article is that Han's Information (300170) has approximately 132,000 shareholders as of August 29, 2025 [1]

Group 1 - The core point of the article is that Han's Information (300170) has approximately 135,000 shareholders as of August 20, 2025 [1]

Group 1 - The company Han's Information stated on September 4 that it currently has no collaboration with Yushu Technology in the field of humanoid robots [2]

Company Overview - Han's Information Technology Co., Ltd. is located in Qingpu District, Shanghai, established on July 15, 2002, and listed on February 1, 2011. The company specializes in ERP software implementation, customer support, and software outsourcing services [1][2]. Financial Performance - For the first half of 2025, Han's Information achieved operating revenue of 1.575 billion yuan, representing a year-on-year growth of 3.54%. The net profit attributable to shareholders was 85.01 million yuan, an increase of 1.90% year-on-year [2]. - The company has distributed a total of 415 million yuan in dividends since its A-share listing, with 125 million yuan distributed over the past three years [3]. Stock Performance - As of September 4, Han's Information's stock price was 17.32 yuan per share, with a market capitalization of 17.517 billion yuan. The stock has increased by 40.22% year-to-date but has seen a decline of 14.76% over the past five trading days [1]. - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) eight times this year, with the most recent appearance on March 7, where it recorded a net buy of -517 million yuan [1]. Shareholder Structure - As of August 29, the number of shareholders for Han's Information was 132,000, a decrease of 2.22% from the previous period. The average number of circulating shares per person increased by 2.27% to 7,379 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by Southern CSI 1000 ETF and a decrease by Hong Kong Central Clearing Limited [3]. Business Segments - The main revenue sources for Han's Information are as follows: General ERP (32.98%), Industry Digitalization-C2M (31.65%), Financial Digitalization-GMC (23.18%), IT Outsourcing-ITO (11.75%), and Other Businesses (0.44%) [1]. Industry Classification - Han's Information is classified under the Shenwan industry as part of the Computer-IT Services II-IT Services III sector, with concepts including SAAS, ERP, AI Agent, Tax Informationization, and MCP [2].

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock will outperform the market index by more than 15% in the next six months [3][10]. Core Insights - The company has shown robust growth in its self-developed software business, with significant advancements in AI application commercialization [3][4]. - In the first half of 2025, the company achieved a revenue of 1.575 billion yuan, representing a year-on-year increase of 3.54%, while the net profit attributable to shareholders was 85 million yuan, up 1.90% year-on-year [7]. - The company has strategically adjusted its business development approach to align with market demands and industry trends, optimizing its business structure by reallocating resources from traditional businesses to new strategic focuses [7]. Financial Performance Summary - The company's self-developed software business (including industrial and financial digitalization) generated a revenue of 903 million yuan in the reporting period, marking a year-on-year growth of 9.98% [7]. - The industrial digitalization segment saw the highest growth rate, with revenues of 533 million yuan, up 13.75% year-on-year, while the financial digitalization segment reported revenues of 370 million yuan, a 4.98% increase [7]. - The overall gross margin for the first half of 2025 reached 34.87%, an increase of 2.43 percentage points year-on-year, driven by significant growth in the gross margin of self-developed software products [7]. - The company’s operating cash flow improved significantly, with a net cash flow from operating activities increasing by 87.65% compared to the same period last year [7]. Future Projections - The company is expected to benefit from the development of AI and digital transformation initiatives, with projected earnings per share (EPS) of 0.24 yuan and 0.31 yuan for 2025 and 2026, respectively, corresponding to price-to-earnings (PE) ratios of 80 and 63 [8][7].